Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

Mastertrader80 Dec. 5 at 8:06 PM

$SMX alerted at 5.50 I made 600 k in 4 days Nobody else and i mean nobody else has alerts like mine People laughed when I said 382 by today and look at the price :p If you want to join the free telegram the link is in my profile 80 positions left!!! $SNSE $TGL $VEEE $QCLS

2 · Reply

UgoGreg Dec. 5 at 8:03 PM

$SNSE https://youtu.be/qxlvNpGKSQc

0 · Reply

TheRealDiamondJim Dec. 5 at 7:41 PM

$SNSE $15 -$17

0 · Reply

vivianhugh Dec. 5 at 7:40 PM

$SNSE $STKH Market sentiment is completely dominated by the bulls. https://www.linkedin.com/feed/update/urn:li:activity:7402708145581752334?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7402708145581752334%2C7402708620339150848%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287402708620339150848%2Curn%3Ali%3Aactivity%3A7402708145581752334%29

0 · Reply

Mastertrader80 Dec. 5 at 7:37 PM

10 new member in less than 5 minutes If you want to catch crazy trades like my alert on $SMX at £5.50 with a price target of £382 Join the telegram link on my profile Once we have 100 members we will open up the discord and that’s when the fun will really happen $TGL $SNSE $ASTS $DEVS https://t.me/+c94fSxIjUINlOTQ0

0 · Reply

Mastertrader80 Dec. 5 at 7:30 PM

$SMX $SNSE $TGL $QCLS $DEVS Hello everyone im the guy that alerted smx at 5.50 with a price target of $382 I made 600k in less than a week just before Christmas and a few people that seen my alert thanked me I’ve set up a completely free telegram for my alerts the link is posted in my profile If your not following then drop me a follow it could change your life See you there and well done to everyone Watching $TGL but it’s a risky play with the split coming looks like a shorts dream !

1 · Reply

beastcrash Dec. 5 at 7:17 PM

$SNSE usually flatline doesn’t end well…I should have sold last fing night

0 · Reply

Mastertrader80 Dec. 5 at 7:11 PM

Of course mate !! Everyone follow me for crazy alerts and I also follow back My discord is going to be live tonight everyone ready We trade crypto and stocks $SMX $SNSE $DEVS

1 · Reply

Mastertrader80 Dec. 5 at 7:03 PM

$SMX $VEEE $SNSE $QCLS My discord will be live tonight everyone ready for Monday If you want to join follow me and subscribe to the posts so you can see when I post the link Well done to everyone that caught my alert on smx with my $382 target price I made 600k would of made almost 4 million but I kept reducing my position Thanks for a great week and nice to meet everyone To the 70 people that have private messages me I’m getting back to everyone ah tonight

1 · Reply

Venom_Rift_412 Dec. 5 at 6:58 PM

$SNSE i’m sticking with Next NRG because every time volume pokes up the price doesn’t crack much that’s a bullish tell for me 👀📈

0 · Reply

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 5 weeks ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 7 weeks ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 12:47 AM EDT - 4 months ago

Sensei (SNSE) Q2 Loss Narrows 31%

Aug 5, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 7 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 10 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 11 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mastertrader80 Dec. 5 at 8:06 PM

2 · Reply

UgoGreg Dec. 5 at 8:03 PM

$SNSE https://youtu.be/qxlvNpGKSQc

0 · Reply

TheRealDiamondJim Dec. 5 at 7:41 PM

$SNSE $15 -$17

0 · Reply

vivianhugh Dec. 5 at 7:40 PM

0 · Reply

Mastertrader80 Dec. 5 at 7:37 PM

0 · Reply

Mastertrader80 Dec. 5 at 7:30 PM

1 · Reply

beastcrash Dec. 5 at 7:17 PM

$SNSE usually flatline doesn’t end well…I should have sold last fing night

0 · Reply

Mastertrader80 Dec. 5 at 7:11 PM

Of course mate !! Everyone follow me for crazy alerts and I also follow back My discord is going to be live tonight everyone ready We trade crypto and stocks $SMX $SNSE $DEVS

1 · Reply

Mastertrader80 Dec. 5 at 7:03 PM

1 · Reply

Venom_Rift_412 Dec. 5 at 6:58 PM

$SNSE i’m sticking with Next NRG because every time volume pokes up the price doesn’t crack much that’s a bullish tell for me 👀📈

0 · Reply

StockAnalyticsAI Dec. 5 at 6:57 PM

$SNSE : Liquidation Arbitrage or Value Trap? Forensic Analysis https://youtu.be/a1UsmBSCgPY?is=dvXamd4z4-QQTE_W via @YouTube

0 · Reply

CatchyLad Dec. 5 at 6:41 PM

$SNSE I’m watching Next NRG because 12 04 still did 924,869 shares and held a 1.20 to 1.26 range the interest stayed alive even on a lighter day ⚡

0 · Reply

beastcrash Dec. 5 at 6:39 PM

$SNSE dry powder

0 · Reply

Lunar_Rift_750 Dec. 5 at 6:38 PM

$SNSE i’m eyeing Next NRG into power hour because when a name with a 43M ish float gets even a modest surge it can reprice in minutes 🚀

0 · Reply

Chrissytina Dec. 5 at 6:32 PM

$EPOW $SNSE Long 😳 if you are long here’s your gun👇🏻🤭

0 · Reply

HandOfStocks Dec. 5 at 6:29 PM

$SNSE took the chance at 8 to buy more - this will go somewhen above 15 again - check the chart

0 · Reply

Profit_Wave_6138 Dec. 5 at 6:26 PM

$SNSE I caught that Next NRG day with 1.33 high and 1.22 low and it still closed about 1.24 that’s strength hiding in plain sight 🔥

0 · Reply

pazienza Dec. 5 at 6:09 PM

$EPOW Come Monday morning, if you're not long this or $SNSE you might want to shoot yourself. 💰

0 · Reply

pazienza Dec. 5 at 5:44 PM

$SNSE If this one caught you off guard you have my full sympathy. That said, you may want to hold the bag for a bit as the chart actually looks pretty friendly. This is not Grandpa's stock market and this can change in the blink of an eye. Stay in the game and don't be chasing $SMX. Your day will come and it will be glorious!

0 · Reply

glennmccarthy Dec. 5 at 5:40 PM

$SMX $SNSE Buying pressure is overwhelmingly dominant. The stock is currently experiencing unprecedented trading volume, signaling strong momentum and the potential for a major breakout. Market forecasts indicate that the stock is expected to rise by 100% by 2026, further increasing its market capitalization, which would be a highly attractive opportunity for investors seeking high-growth prospects.

1 · Reply

Chrissytina Dec. 5 at 5:39 PM

$SNSE Did anybody get that last dip? I got the earlier one at $7.70🤷🏼‍♀️

0 · Reply

Mastertrader80 Dec. 5 at 5:17 PM

$QCLS this will run ! Market was a bit weird today a lot of traders kept pulling funds for smx chasing It will settle over the weekend Next weeks watchlist Don’t forget to follow me $VEEE $SNSE $IRBT

1 · Reply

Market Cap	10.34M
Revenue (ttm)	0.00
Net Income (ttm)	-30.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,042,686
Avg Vol	57,416
Day's Range	N/A - N/A
Shares Out	1.26M
Stochastic %K	96%
Beta	0.32
Analysts	Hold
Price Target	$35.00